{"id":60970,"date":"2024-02-28T07:18:18","date_gmt":"2024-02-28T07:18:18","guid":{"rendered":"https:\/\/medsname.com\/selgin\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"selgin","status":"publish","type":"product","link":"https:\/\/medsbase.com\/bg\/product\/selgin\/","title":{"rendered":"Selgin"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 \u0411\u044a\u0440\u0437 \u043e\u0442\u0433\u043e\u0432\u043e\u0440<\/h3>\n

Selgin<\/strong> \u0435 \u043e\u0440\u0430\u043b\u0435\u043d selegiline<\/strong> (5 mg) tablet \u2014 a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> \u0438\u0437\u043f\u043e\u043b\u0437\u0432\u0430 \u0441\u0435 \u0437\u0430 \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u043d\u0430 \u0431\u043e\u043b\u0435\u0441\u0442 \u043d\u0430 \u041f\u0430\u0440\u043a\u0438\u043d\u0441\u043e\u043d<\/strong>. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Selegiline is metabolised to L-amphetamine and L-methamphetamine<\/strong>, which can contribute to insomnia — take morning doses only. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. \u0412\u0430\u0436\u043d\u043e:<\/strong> avoid combination with most antidepressants (SSRIs, SNRIs, TCAs), opioids such as pethidine and tramadol, and dextromethorphan — risk of \u0441\u0435\u0440\u043e\u0442\u043e\u043d\u0438\u043d\u043e\u0432 \u0441\u0438\u043d\u0434\u0440\u043e\u043c<\/em>.<\/p>\n<\/div>\n

\n\u041a\u0430\u043a\u0432\u043e \u043f\u043e\u043b\u0443\u0447\u0430\u0432\u0430\u0442\u0435 \u0441 MedsBase:<\/strong> \u041f\u0440\u043e\u0438\u0437\u0432\u043e\u0434\u0438\u0442\u0435\u043b, \u0441\u0435\u0440\u0442\u0438\u0444\u0438\u0446\u0438\u0440\u0430\u043d \u043e\u0442 WHO-GMP \u00b7 \u0414\u0438\u0441\u043a\u0440\u0435\u0442\u043d\u0430 \u043e\u043f\u0430\u043a\u043e\u0432\u043a\u0430 \u00b7 \u0414\u043e\u0441\u0442\u0430\u0432\u043a\u0430 \u043f\u043e \u0446\u0435\u043b\u0438\u044f \u0441\u0432\u044f\u0442 \u00b7 \u041d\u0430\u0434 1400 \u043f\u043e\u0442\u0432\u044a\u0440\u0434\u0435\u043d\u0438 \u043e\u0442\u0437\u0438\u0432\u0430 \u043e\u0442 \u043a\u043b\u0438\u0435\u043d\u0442\u0438<\/a>\n<\/div>\n

\ud83d\udce6 \u0412\u0441\u044f\u043a\u0430 \u043f\u043e\u0440\u044a\u0447\u043a\u0430 \u0435 \u043f\u043e\u043a\u0440\u0438\u0442\u0430 \u043e\u0442 \u043d\u0430\u0448\u0430\u0442\u0430 \u041f\u043e\u043b\u0438\u0442\u0438\u043a\u0430 \u0437\u0430 \u043f\u043e\u0432\u0442\u043e\u0440\u043d\u0430 \u0438\u0437\u043f\u0440\u0430\u0442\u043a\u0430<\/strong><\/a> \u2014 \u0430\u043a\u043e \u0432\u0430\u0448\u0430\u0442\u0430 \u043f\u0440\u0430\u0442\u043a\u0430 \u043d\u0435 \u043f\u0440\u0438\u0441\u0442\u0438\u0433\u043d\u0435 \u0432 \u0440\u0430\u043c\u043a\u0438\u0442\u0435 \u043d\u0430 20 \u0440\u0430\u0431\u043e\u0442\u043d\u0438 \u0434\u043d\u0438, \u043d\u0438\u0435 \u044f \u0438\u0437\u043f\u0440\u0430\u0449\u0430\u043c\u0435 \u043e\u0442\u043d\u043e\u0432\u043e.<\/p>\n

\u0417\u0430\u0449\u043e \u0434\u0430 \u043f\u043e\u0440\u044a\u0447\u0432\u0430\u0442\u0435 \u043e\u0442 MedsBase<\/h3>\n

\u041d\u0430\u0448\u0438\u0442\u0435 \u0433\u0435\u043d\u0435\u0440\u0438\u0447\u043d\u0438 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0430 \u0441\u0435 \u0434\u043e\u0441\u0442\u0430\u0432\u044f\u0442 \u043e\u0442 \u043f\u0440\u043e\u0438\u0437\u0432\u043e\u0434\u0438\u0442\u0435\u043b\u0438, \u0441\u0435\u0440\u0442\u0438\u0444\u0438\u0446\u0438\u0440\u0430\u043d\u0438 \u043e\u0442 WHO-GMP, \u0438 \u0441\u0435 \u0438\u0437\u043f\u0440\u0430\u0449\u0430\u0442 \u043f\u043e \u0446\u0435\u043b\u0438\u044f \u0441\u0432\u044f\u0442 \u0432 \u0434\u0438\u0441\u043a\u0440\u0435\u0442\u043d\u0430, \u043e\u0431\u0438\u043a\u043d\u043e\u0432\u0435\u043d\u0430 \u043e\u043f\u0430\u043a\u043e\u0432\u043a\u0430 \u2014 \u0431\u0435\u0437 \u0438\u043c\u0435 \u043d\u0430 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u043e\u0442\u043e \u0432\u044a\u043d\u0448\u043d\u043e \u043d\u0430 \u043f\u0440\u0430\u0442\u043a\u0430\u0442\u0430. \u041f\u043b\u0430\u0449\u0430\u043d\u0438\u044f\u0442\u0430 \u0441 \u043a\u0430\u0440\u0442\u0430 \u0441\u0435 \u043e\u0431\u0440\u0430\u0431\u043e\u0442\u0432\u0430\u0442 \u0447\u0440\u0435\u0437 \u0440\u0435\u0433\u0443\u043b\u0438\u0440\u0430\u043d \u043f\u0440\u043e\u0446\u0435\u0441\u043e\u0440 (\u043e\u043f\u0438\u0441\u0430\u043d\u0438\u0435\u0442\u043e \u043d\u0430 \u0438\u0437\u0432\u043b\u0435\u0447\u0435\u043d\u0438\u0435\u0442\u043e \u0432\u043a\u043b\u044e\u0447\u0432\u0430 \u0440\u0435\u0433\u0443\u043b\u0438\u0440\u0430\u043d \u043f\u0440\u043e\u0446\u0435\u0441\u043e\u0440 \u0437\u0430 \u043f\u043b\u0430\u0449\u0430\u043d\u0435 \u0441 \u043a\u0430\u0440\u0442\u0430 \u2014 \u043d\u0438\u043a\u043e\u0433\u0430 \u201cMedsBase\u201d \u0438\u043b\u0438 \u0438\u043c\u0435 \u043d\u0430 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u043e). \u041f\u0440\u0438\u0435\u043c\u0430\u0442 \u0441\u0435 \u0441\u044a\u0449\u043e \u043a\u0440\u0438\u043f\u0442\u043e\u0432\u0430\u043b\u0443\u0442\u0438 \u0438 \u0431\u0430\u043d\u043a\u043e\u0432 \u043f\u0440\u0435\u0432\u043e\u0434 SEPA. \u0412\u0441\u044f\u043a\u0430 \u043f\u043e\u0440\u044a\u0447\u043a\u0430 \u0435 \u043f\u043e\u0434\u043a\u0440\u0435\u043f\u0435\u043d\u0430 \u043e\u0442 \u043d\u0430\u0448\u0430\u0442\u0430 \u043f\u043e\u043b\u0438\u0442\u0438\u043a\u0430 \u0437\u0430 \u0433\u0430\u0440\u0430\u043d\u0442\u0438\u0440\u0430\u043d\u043e \u043f\u0440\u0435\u0438\u0437\u043f\u0440\u0430\u0449\u0430\u043d\u0435.<\/p>\n

What Is Selgin?<\/h2>\n

Selgin is an oral tablet containing selegiline 5 mg<\/strong>. selegiline is a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> originally introduced as Eldepryl \/ Jumex<\/strong>. Selgin is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n

Selegiline was the first MAO-B inhibitor used in Parkinson disease, in clinical use since the 1980s. It can be used as monotherapy<\/em> in early Parkinson disease (modest symptomatic benefit, may delay the need for levodopa by months) or as \u0434\u043e\u043f\u044a\u043b\u043d\u0438\u0442\u0435\u043b\u043d\u0430 \u0442\u0435\u0440\u0430\u043f\u0438\u044f<\/em> to levodopa to reduce “wearing-off” between doses. Its distinctive feature among MAO-B inhibitors is that it is metabolised to amphetamine derivatives, which contribute to a mild stimulant effect — useful for fatigue but a frequent cause of insomnia.<\/p>\n

How Does Selgin (selegiline) Work?<\/h2>\n

In the brain, dopamine is degraded mainly by monoamine oxidase type B (MAO-B). Selegiline irreversibly inactivates MAO-B at standard doses (5–10 mg\/day), so dopamine released from surviving neurones lingers longer in the synapse. The result: smoother symptom control and a longer benefit from each levodopa dose. Selegiline is also metabolised to L-amphetamine and L-methamphetamine, which independently contribute mild stimulant and dopaminergic effects. Above 10 mg\/day, selectivity for MAO-B is lost and MAO-A inhibition becomes clinically meaningful — tyramine restriction then becomes important.<\/p>\n

Comparing the MAO-B Inhibitors<\/h2>\n

The three MAO-B inhibitors used in Parkinson disease — selegiline, rasagiline and safinamide — share a common mechanism but differ meaningfully in metabolites, dosing and clinical positioning:<\/p>\n\n\n\n\n\n\n\n\n\n
\u0425\u0430\u0440\u0430\u043a\u0442\u0435\u0440\u0438\u0441\u0442\u0438\u043a\u0430<\/th>\nSelegiline<\/th>\nRasagiline<\/th>\nSafinamide<\/th>\n<\/tr>\n<\/thead>\n
\u0422\u0438\u043f\u0438\u0447\u043d\u0430 \u0434\u043e\u0437\u0430<\/td>\n5–10 mg\/day<\/td>\n0.5–1 mg\/day<\/td>\n50–100 mg\/day<\/td>\n<\/tr>\n
Active metabolites<\/td>\nAmphetamine + methamphetamine<\/td>\nAminoindan (non-amphetamine)<\/td>\nNo active stimulant metabolite<\/td>\n<\/tr>\n
Glutamate effect<\/td>\n\u041d\u0435<\/td>\n\u041d\u0435<\/td>\n\u0414\u0430<\/strong> — sodium-channel\/glutamate-release modulation<\/td>\n<\/tr>\n
\u041f\u043e\u043a\u0430\u0437\u0430\u043d\u0438\u0435<\/td>\nMonotherapy or adjunct<\/td>\nMonotherapy or adjunct<\/td>\nAdjunct only<\/strong> — for fluctuating PD on levodopa<\/td>\n<\/tr>\n
Insomnia risk<\/td>\nHigher (amphetamine metabolites)<\/td>\n\u041d\u0438\u0441\u043a\u0430<\/td>\n\u041d\u0438\u0441\u043a\u0430<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Who Is Selgin For?<\/h2>\n

Selgin is appropriate for adults with Parkinson disease — either as initial monotherapy in early disease (when symptoms are mild and the patient is reluctant to start levodopa) or as adjunct to levodopa in patients with end-of-dose “wearing-off”. Older patients prone to insomnia may tolerate rasagiline or safinamide better. Not appropriate during current SSRI\/SNRI\/TCA therapy or for patients planning to take pethidine, tramadol or other contraindicated medications.<\/p>\n

\u0414\u043e\u0437\u0438\u0440\u0430\u043d\u0435 \u0438 \u043f\u0440\u0438\u043b\u043e\u0436\u0435\u043d\u0438\u0435<\/h2>\n

\u0421\u0442\u0430\u043d\u0434\u0430\u0440\u0442\u043d\u0430\u0442\u0430 \u0434\u043e\u0437\u0430 \u0437\u0430 \u0432\u044a\u0437\u0440\u0430\u0441\u0442\u043d\u0438 \u0435 5 mg once daily with breakfast<\/strong>, increased to 5 mg twice daily (breakfast and lunch) after 1–2 weeks<\/strong> if needed for symptom control. Avoid evening doses<\/em> — the amphetamine metabolites cause insomnia. Maximum 10 mg\/day at standard MAO-B selectivity. Doses up to 20–30 mg\/day have been used historically but cross into non-selective MAO inhibition with full tyramine-diet implications.<\/p>\n\n\n\n\n\n\n\n
\u0424\u0430\u0437\u0430<\/th>\n\u0414\u043e\u0437\u0430<\/th>\n\u0412\u0440\u0435\u043c\u0435\u0432\u0438 \u0441\u0440\u043e\u043a<\/th>\n<\/tr>\n<\/thead>\n
Week 1–2 (initiation)<\/td>\n5 mg \u0432\u0435\u0434\u043d\u044a\u0436 \u0434\u043d\u0435\u0432\u043d\u043e<\/td>\nWith breakfast<\/td>\n<\/tr>\n
\u041f\u043e\u0434\u0434\u044a\u0440\u0436\u0430\u0449\u0430 \u0434\u043e\u0437\u0430<\/td>\n5 mg \u0434\u0432\u0430 \u043f\u044a\u0442\u0438 \u0434\u043d\u0435\u0432\u043d\u043e<\/td>\nBreakfast and lunch — never evening<\/td>\n<\/tr>\n
Maximum at MAO-B selectivity<\/td>\n10 mg\/day<\/td>\nBeyond this, tyramine restriction needed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
⚠ Tyramine and the “cheese effect”<\/strong> At standard MAO-B-selective doses, dietary tyramine restriction is generally \u043d\u0435<\/em> required. However, MAO-B selectivity is dose-dependent — selegiline above 10 mg\/day, rasagiline above 1 mg\/day, and safinamide above 100 mg\/day lose selectivity and inhibit peripheral MAO-A as well. At those doses, tyramine-rich foods (aged cheeses, cured meats, broad beans, fermented soya, draught beer) can trigger a hypertensive crisis. Stay within prescribed doses to avoid this risk.<\/div>\n

\u0427\u0435\u0441\u0442\u043e \u0441\u0440\u0435\u0449\u0430\u043d\u0438 \u0441\u0442\u0440\u0430\u043d\u0438\u0447\u043d\u0438 \u0435\u0444\u0435\u043a\u0442\u0438<\/h2>\n

Insomnia (very common — the most common reason for discontinuation), headache, nausea, dizziness, postural hypotension, dry mouth, increased liver enzymes. Less common: confusion, hallucinations, agitation, mood changes. With levodopa: increased dyskinesia, may need to lower the levodopa dose by 10–30%.<\/p>\n

⚠ Serotonin syndrome — dangerous interactions<\/strong> Combining a MAO-B inhibitor with serotonergic drugs can cause \u0441\u0435\u0440\u043e\u0442\u043e\u043d\u0438\u043d\u043e\u0432 \u0441\u0438\u043d\u0434\u0440\u043e\u043c<\/em>: agitation, sweating, tremor, hyperreflexia, fever, diarrhoea, in severe cases seizures and death. Avoid:<\/strong> SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram), SNRIs (venlafaxine, duloxetine), tricyclics (amitriptyline, imipramine), pethidine (meperidine), tramadol, dextromethorphan, methadone, St John’s wort, MDMA. Wash-out periods:<\/strong> stop fluoxetine 5 weeks before starting MAO-B inhibitor; stop other SSRIs\/SNRIs at least 2 weeks before; do not start fluoxetine within 2 weeks of stopping the MAO-B inhibitor.<\/div>\n

\u041b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u0438 \u0438 \u0445\u0440\u0430\u043d\u0438\u0442\u0435\u043b\u043d\u0438 \u0432\u0437\u0430\u0438\u043c\u043e\u0434\u0435\u0439\u0441\u0442\u0432\u0438\u044f<\/h2>\n